Compare Adaptive Biotechnologies Corp (ADPT) vs Equinix Inc (EQIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Equinix Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Equinix Inc trades at $1,033.5 (market cap $101.87B). The key difference: Equinix Inc is far larger — about 25.2× Adaptive Biotechnologies Corp's market cap, and Equinix Inc pays a 2% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | EQIX | |
|---|---|---|
Market Cap | $4.04B | $101.87B |
Sector | Health | Real Estate |
52-Week High | $25.45 | $1.12K |
52-Week Low | $12.30 | $726.09 |
Enterprise Value | $4.10B | $123.00B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
Equinix (EQIX) trades at $1,069.17, up 2.47% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $4.83, beating estimates, and raised its long-term growth outlook amid strong AI infrastructure demand. Revenue grew to $9.22 billion in 2025, with net income margin improving to 15.63%. However, valuation multiples like P/E of 66.44 and EV/EBITDA of 27.58 are elevated, and net cash flow turned negative in 2025 due to heavy investing activities.
The outlook is supported by robust analyst sentiment with a $1,120 consensus price target and 74.51% buy ratings, but risks include high leverage with debt-to-asset ratio rising to 47.13% in 2025 and earnings misses in two of the last three quarters. Investors should weigh growth potential against valuation and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
